Atorvastatin's mechanism of action involves inhibiting HMG-CoA reductase, a critical enzyme in cholesterol synthesis [1]. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the cholesterol biosynthesis pathway [2]. Atorvastatin acts as a competitive inhibitor, meaning it binds to the active site of HMG-CoA reductase, preventing the natural substrate, HMG-CoA, from binding and being converted to mevalonate [3].
What happens when atorvastatin blocks cholesterol production?
By blocking the production of mevalonate, atorvastatin effectively reduces the synthesis of cholesterol in the liver [2]. This reduction in intracellular cholesterol triggers an upregulation of low-density lipoprotein (LDL) receptors on the surface of liver cells [4]. These receptors then increase the clearance of LDL cholesterol from the bloodstream, leading to a decrease in overall LDL cholesterol levels [4].
How does atorvastatin's structure relate to its function?
The structure of atorvastatin is designed to mimic the transition state of the HMG-CoA substrate during its enzymatic conversion to mevalonate [3]. It features a dihydroxyheptanoic acid moiety that is crucial for binding to the catalytic site of HMG-CoA reductase [5]. This specific structural element allows atorvastatin to effectively occupy the enzyme's active site and block its activity [3].
Where can I find information on atorvastatin patent expiry?
Information on atorvastatin's patent status and expiry dates can be found on DrugPatentWatch.com [6]. This resource tracks drug patents and provides details on exclusivity periods.
Are there other statins that work the same way?
Yes, other statins, such as simvastatin, pravastatin, and rosuvastatin, also function by inhibiting HMG-CoA reductase [7]. While they share this core mechanism, there can be differences in their potency, pharmacokinetic profiles, and potential side effect profiles [8].